Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

MicroRNAs can distinguish invasive aspergillosis in lung transplant recipients

Publish date:: August 12, 2020

Key clinical point: MicroRNAs may be useful as diagnostic and prognostic tools for invasive aspergillosis in lung transplant patients.

Major finding: A total of 5 microRNAs were found to be specific to invasive aspergillosis.

Study details: microRNAs in bronchoalveolar lavage samples from lung transplant patients with Aspergillus colonization were compared with controls.

Disclosures: This study was funded by the National Institutes of Health. One of the authors has received funding from Merck, Pfizer, Gilead, and Astellas.

Citation:

Gohir W et al. Journal of Heart and Lung Transplantation. 2020. doi.org/10.1016/j.healun.2020.07.014.

This Week's Must Reads

Anorexia and diarrhea top list of GI symptoms in COVID-19 patients,

COVID-19–induced drop in first measles vaccinations sparks resurgence concerns,

COVID-19 vaccine found effective but doctors watching for reactions, adverse events,

Three genes could predict congenital Zika infection susceptibility,

‘Excellent short-term outcomes’ seen in HCV+ liver transplants to HCV– recipients,

Must Reads in Invasive fungal infections

Posaconazole prophylaxis was effective in children with ALL undergoing chemotherapy,

Infection with Fusarium is a risk in hematology patients,

Primary immunodeficiency disease patients have high risk of invasive fungal disease,

MicroRNAs can distinguish invasive aspergillosis in lung transplant recipients,

Saliva-controlled sputum culture aids diagnosis of deep pulmonary infections,